Tweets
ACR's State-by-State Report Cards for Rheumatic Disease
New report examines access, affordability, and activity and lifestyle factors in all 50 states and DC evaluating how easy it is to live with a rheumatic disease in your state.
https://t.co/MmzG9oTfnq https://t.co/UhSM22PMf5
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
RHEUMATOLOGISTS - How do you deal with skin Psoriasis (PSO) activity in your Psoriatic Arthritis Pts?
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
#ACR22 abstracts: 0220
Do you think social media can enhance your rheuma medical education, research or professional development? @anzypanzywanzy @anjmsantiago @PhRheumaJr @rheum4you @RHEUMarampa @RheumaRambolMD @doktora_ging #ACRambassador
📌https://t.co/SZB4p0WNu8
Lisa 🐳🐬 @rheumarhyme ( View Tweet )
3 years 10 months ago
New CDC data on vaccination/boosters during BA.5 wave for deaths, age 50+
https://t.co/HGyjNwUveD
Compared w/unvaccinated:
—92% reduction of death for 4 shots
—No difference in reduction between 3 and 2 shots (~82%)
[that's a 12-fold ⬇️risk of death for 4 shots in July 2022] https://t.co/3JDjCLbEyh
Links:
Eric Topol @EricTopol ( View Tweet )
3 years 10 months ago
IBD Ups Risk of Psoriatic Disease
Findings of a new study suggest a causal effect between inflammatory bowel disease (IBD) and psoriasis (PSO) as well as psoriatic arthritis (PsA), but not vice versa.
https://t.co/twam1BcG8I https://t.co/8PFObkNn4J
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
STAR-RA study - real world claims data shows tofacitinib doesnt increase malignancy risk. Study of 83,295 pts (10,504 TOFA). Risk of malignancy w/ TOFA not increased (HR 1.01) w/ RWE or RCT-duplicate cohort (HR 1.1; 95% CI 0.85, 1.62) https://t.co/GIIvs2cK3s
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
EMA has approved 86 biosimilar medicines since 2006 and has issued a harmonizing statement for EU countries that biosimilars are interchangeable with their reference medicine or with an equivalent biosimilar. https://t.co/ajsP1ulZTQ
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
RINOMAX Trial studied single dose of 500 mg rituximab IV in myasthenia gravis - 47 MG pts randomized to RTX or PBO, after 4 mos RTX response (71% vs 29%) superior to PBO. Further studies are needed https://t.co/XvAWRH8fUz
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
Deep Vein Thrombosis reviewed in current Annals of Internal Medicine - VTE is the 3rd most common CVD, seen in 5% of population. Half of VTE assoc w/ transient preventable risk factors. Direct oral anticoagulants are effective and safer https://t.co/6utxivuwf6
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
Propensity matched pairs (n=237 872) of perioperative pts - gabapentin users and nonusers shows perioperative gabapentin use had significantly more delirium (RR 1.28), antipsychotic Rx (1.17 ) & pneumonia (1.11) vs nonusers post surgery https://t.co/UAZs7Vqy6O
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
Colchicine vs cimetidine in PFAPA (Periodic fever, aphthous stomatitis, pharyngitis, adenitis) syndrome. 72 pts given COL vs CIM x 3 mos: # of febrile attacks was significantly decreased by both Rx (noninferior to each other) https://t.co/MO7IQ0e8gf
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
Metals & Hyperuricemia (HU) (20 studies, 63,283 participants): Increased HUA risk arsenic (OR 1.7), calcium (OR 1.76), cadmium (OR 1.19), & lead (OR 1.56), BUT lower w/ molybdenum (OR 0.8). No effect w/ Cu, Fe, Mg, Zn, Cd, Co, Al, Hg, Tl https://t.co/xmdBCCBuEk
Links:
Dr. John Cush @RheumNow ( View Tweet )
3 years 10 months ago
